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Abstract
The number and importance of intrinsically disordered proteins (IUP), known to be involved in various human disorders, are
growing rapidly. To test for the generalized implications of intrinsic disorders in proteins involved in Neurodegenerative
diseases, disorder prediction tools have been applied to three datasets comprising of proteins involved in Huntington
Disease (HD), Parkinson’s disease (PD), Alzheimer’s disease (AD). Results show, in general, proteins in disease datasets
possess significantly enhanced intrinsic unstructuredness. Most of these disordered proteins in the disease datasets are
found to be involved in neuronal activities, signal transduction, apoptosis, intracellular traffic, cell differentiation etc. Also
these proteins are found to have more number of interactors and hence as the proportion of disorderedness (i.e., the length
of the unfolded stretch) increased, the size of the interaction network simultaneously increased. All these observations
reflect that, ‘‘Moonlighting’’ i.e. the contextual acquisition of different structural conformations (transient), eventually may
allow these disordered proteins to act as network ‘‘hubs’’ and thus they may have crucial influences in the pathogenecity of
neurodegenerative diseases.
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Introduction
Of late there has been a considerable shift in the protein
sequence-structure-function paradigm. With the ever emerging
population of Disordered, Natively Unfolded or Intrinsically
Unstructured Proteins (IUPs), it is now generally understood that
the structure-function correlation is a contextual phenomenon for
a protein molecule. For a metabolic enzyme with an ‘‘ordered’’
structure, the particular conformation required for ‘‘induced fit’’
may have a very high negative conformational free energy chosen
by evolutionary selection pressure over time and thus the issue of
‘‘context’’ may appear to be irrelevant in these cases. Although
exceptions to these classical views had been reported earlier where
a well characterized enzyme was found to have altogether different
function in a different context, and conform to a somewhat
polymorphic model [1–3].
IUPs do not form a fixed three dimensional structure under
physiological conditions either in their entireties or they may
contain Intrinsically Disordered Regions (IDRs). Their structures
resemble the denatured states of ordered proteins, best described
as an ensemble of rapidly interconverting alternative structures,
which nevertheless, are their native, functional states [4]. They
take up different structures upon binding to different targets, and
thereby exhibit functional flexibility through the formation of
fuzzy complexes [2]. The extent of structural variations, upon
functional binding of a ligand, ranges from slight conformational
adjustments seen in allosterism to a drastic conformational switch
or loss of structure [1]. Interestingly it is also known that intrinsic
disorder is more prevalent (35–51%) in eukaryotic organisms
whereas only 7–33% and 9–37% of bacteria and archaea proteins,
respectively, contain long unstructured regions as calculated by
disorder prediction tool PONDR VL-XT [5]. Paradoxically this
observation conforms to the fact that the number of components
in the genome and the proteome for an organism are uncorrelated.
Considering the enormous complexity of functions that a
eukaryotic proteome needs to handle starting with the information
from a single gene sequence, IUPs provide another level of
variation in its portfolio in addition to other known events like
alternative splicing or post-translational modifications. Under-
standably, this is the case for higher organisms having limited
genome size.
The conformational promiscuity or ‘‘pliability’’ of the IUPs
makes them capable of ‘‘multitasking’’ or ‘‘moonlighting’’ [3].
Although these proteins lack regular structures, the IUPs carry out
important biological functions including regulation of cell division,
chaperone activity, signaling and transcriptional and translational
control [6]. In an intricate protein-protein interaction network,
they, therefore, play the role of ‘‘hubs’’ or ‘‘nodes’’ and provide
‘‘robustness’’. From a systems biology point of view, alterations
(e.g., mutations) in the genes coding for the ‘‘hub’’ protein would
not be advantageous as they might lead to partial or complete
collapse of the network. This network ‘‘failure’’ might, in turn, lead
to several functional abnormalities promulgating disease patho-
genesis. Evaluating the involvement and influence of IUPs in
monogenic as well as multifactorial complex disorders of late onset
type may give us important clues about the disease mechanisms.
Recently, it has been found that disorder is very common in
complex human diseases. Iakoucheva et al. predicted, using the
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cancer associated proteins contain regions of disorder of $30
residues. In contrast, only 13% of proteins from a set of proteins
with well-defined ordered structures contain such long regions of
predicted disorder [6]. In the same study 66% of cellular signaling
associated proteins were found to be enriched in disorder. In
another study using the same tool, Cheng et al. have shown that
57% of the cardiovascular disease associated proteins contain 30
or more consecutive residues, predicted to be disordered [7]. They
also used PONDR VL-XT as the disorder prediction tool. Thus
disorder was found to be significantly higher among these disease-
associated proteins than the total pool of eukaryotic proteins in
SwissProt database, 47% of which contained disordered regions by
the same definition. In another study, Cheng et al., using the same
algorithm, estimated that among human disease-associated
proteins, including autoimmune diseases, cancer, cardiovascular
diseases, diabetes, and neurodegenerative diseases, approximately
69% were expected to contain disorder regions of $30 consecutive
amino acid residues using PONDR VL-XT algorithm [8]. Among
those disease associated proteins, 21% were identified to have roles
in cell signaling pathways and were found to contain long
disordered regions, compared to rest 8% of the cell signaling
proteins that were predicted to be predominately ordered. For the
entire set of disease-associated proteins with long disordered
regions, 48% were predicted to be not participating in signaling
[8].
The group of neurodegenerative disorders currently comprise of
about 32 known types of different diseases. Interestingly, in many
of the neurodegenerative diseases, the common feature is
misfolding and aggregation of proteins, the major contributory
factor of neurotoxicity [9]. They exert toxicity by disrupting
intracellular transport, overwhelming protein degradation path-
ways, and/or disturbing vital cell functions [10]. Some of the key
proteins that cause neurodegenerative diseases like APP, SNCA or
Htt contain IDRs or they themselves are IUPs [11–17]. Recently
we have provided evidence that HYPK, an interacting partner of
Htt, whose mutation causes HD, is an IUP [11]. It would be
interesting therefore to evaluate the potential role of IUPs in
disease processes [18]. In this article, we have dealt with three of
them; e.g. Huntington’s disease (HD), Alzheimer’s disease (AD)
and Parkinson’s disease (PD). They are the commonest among
human neurodegenerative diseases, significantly affecting a large
population [19]. HD is an autosomal dominant disease caused by
a trinucleotide (CAG) repeat expansion beyond 36 in the
Huntingtin (htt) gene that produces an altered form of the Htt
protein. The elongated poly Q sequence thus produced is believed
to initiate protein misfolding resulting in nuclear aggregation in
the cells of striatum and cortex [20,21]. Alzheimer’s disease is
characterized by the presence of two lesions: the plaque, an
extracellular lesion made up largely of the b-amyloid (Ab) peptide,
and the tangle, an intracellular lesion made up largely of the
cytoskeletal protein tau. The pathological hallmark of Parkinson’s
disease is the deposition of Lewy bodies, cytoplasmic inclusions
composed largely of a-synuclein, within the dopaminergic neurons
[19]. Using bioinformatics tools here we have characterized the
IUPs involved in these diseases and analyzed their functional
significance.
Results
Unstructured Proteins are Prevalent in
Neurodegenerative Diseases
Following the protocols described in the methods section, we
developed six independent datasets. After stringent filtering of the
retrieved data from literature and interaction databases, three
disease datasets, named ‘‘HD dataset’’, ‘‘PD dataset’’, and ‘‘AD
dataset’’, were generated. Three control datasets were also
constructed. ‘‘Control dataset 1’’ comprised of 17159 hits from
SwissProt (release 55.0), ‘‘control dataset 2’’ comprised of 264
human enzymes which have known PDB structures and ‘‘control
dataset 3’’ consisted of 117 human proteins implicated in breast
cancer which were also derived from SwissProt.
Using the described selection criteria, the disorder indices of the
proteins in all six independently constructed datasets were
calculated. It was immediately apparent that unstructuredness
was significantly (at 95% level of significance) prevalent among
proteins of ‘‘AD dataset’’ and ‘‘HD dataset’’ with respect to the
‘‘control dataset 1’’. For the ‘‘PD dataset’’, however, the
prevalence was not significant (the data was found to be significant
at the 90% level) with respect to the ‘‘control dataset 1’’. The
‘‘control dataset 2’’ was constructed to ensure that ‘‘unstructured-
ness’’ may not be necessary for all the genetic diseases, for example
in metabolic disorders, where the involved proteins are predom-
inantly structured enzymes. When compared to ‘‘control dataset
2’’, unstructuredness was found to be significantly prevalent in all
the disease datasets. We constructed the ‘‘control dataset 3’’ to
check whether the involvement of IUPs was specific for
neurodegenerative diseases or it generally related to disease.
Intriguingly, unstructuredness was not significantly enriched (at
95% level of significance) in the ‘‘control dataset 3’’, which
comprised of proteins implicated in breast cancer, compared to
‘‘control dataset 1’’; whereas in comparison to ‘‘control dataset 2’’
it was significant. The summary of these results, along with the Z
scores calculated is shown in Table 1.
When we considered all the 352 proteins that have experimen-
tally validated implications in HD, PD or AD (i.e., a non-
redundant combination of ‘‘HD dataset’’, ‘‘PD dataset’’ and ‘‘AD
dataset’’ – designated as ‘‘disease dataset’’), we found ,80% of
them were unstructured compared to 73.4% and 47.7% in
‘‘control dataset 1 and 2’’ respectively (Figure 1A). Z values
calculated for the 352 proteins compared to ‘‘control dataset 1 and
2’’ were 3.27 and 6.5 respectively signifying prevalence (at 99%
level of significance) of unstructured proteins in disease datasets. It
was then prudent to ask whether the proteins designated as
‘‘disordered’’ in the disease datasets contained lengthier unstruc-
tured regions compared to the disordered proteins in ‘‘control
dataset 1 and 2’’. We plotted percentage of proteins containing
disordered regions against the number of consecutive amino acids
residues predicted to be disordered and found in comparison to
‘‘control dataset 1’’, a significant prevalence of lengthier
unstructured regions in proteins from ‘‘HD dataset’’ only but
compared to ‘‘control dataset 2’’, all the disease datasets were
enriched in lengthier unstructured proteins. (Figure 1B).
Unstructuredness is Prevalent in Hub Proteins in the HD,
PD and AD datasets
There is an intuition that with increasing disorderedness,
number of interactors of a protein would also increase [22,23].
In order to see whether the number of interactors of a protein
increased with unstructuredness, we initially counted the numbers
of ‘‘hub’’ and ‘‘end’’ proteins among the proteins which have
experimentally validated influence in disease processes and present
in HD, PD and AD datasets. Almost 49% (72 out of 147), 51% (33
out of 65) and 53% (74 out of 140) proteins of HD, PD and AD
datasets respectively were found to have more than 10 interactors
(hub proteins). Among these hub proteins 92, 85 and 88% of the
proteins in HD, PD and AD datasets, respectively, were found to
be unstructured. In contrast, 74, 65 and 76% of the end proteins in
IUPs in Neurodegeneration
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we considered all the hub and end proteins in these three disease
datasets together, unstructured proteins were found to be
significantly (P value=0.0133) prevalent among the hub proteins
in the disease datasets (88.3%) compared to the end proteins
(71.6%) (Figure 1C).
However, to ensure that all possible biasness was eliminated, we
used a validation protocol where the same calculations were done
with varying cutoff values to define ‘‘hub’’ and ‘‘end’’. Interest-
ingly, with these independent analyses also a similar trend was
observed. Here, rather than defining a protein with more than 10
interactors as a ‘‘hub’’, those with more than 5 or 20 interactors in
the disease datasets were defined as ‘‘hubs’’ respectively (similarly
those with less than 5 or 20 interactors were termed ‘‘ends’’
respectively), in two consecutive cases, and the ‘‘hub proteins’’
from all these three datasets were considered together to estimate
the number of unstructured proteins among them. Almost 86% of
the ‘‘hub proteins’’ were found to be unstructured when proteins
with more than 5 interactors were defined as ‘‘hubs’’ (Figure 1D).
In contrast 65% of the ‘‘end proteins’’ were found to be
unstructured. Likewise 89.6% of the ‘‘hub proteins’’ were found
to be unstructured when proteins with more than 20 interactors
were called ‘‘hubs’’. In contrast 73.8% of the ‘‘end proteins’’ were
found to be unstructured (Figure 1E).
Functions of the IUPs in Neurodegenerative Diseases
(HD, PD and AD)
We carried out functional annotations of the proteins in the
disease datasets using the ‘‘Biological Process’’ annotation tool
available in ‘‘PANTHER’’ database. Primarily we looked for the
processes which were significantly enriched in disease proteins
compared to total human proteome dataset. Subsequently we
investigated whether those processes were enriched with unstruc-
tured proteins or not. Interestingly, processes like neuronal
activities, signal transduction, cell cycle, intracellular traffic,
apoptosis, protein targeting and metabolism etc., appeared to be
the major processes involved in disease pathogenesis. Proteins
participating in these processes were significantly enriched in
disease datasets as well as they were populated with unstructured
proteins.
The proteins in ‘‘HD dataset’’ were found to have significantly
enriched participation in ‘‘biological processes’’ like neuronal
activities, cell proliferation and differentiation, cell structure and
motility, apoptosis and its regulation, carbohydrate metabolism,
protein metabolism, cell cycle, intracellular protein traffic, electron
transport and protein targeting and localization etc. (Figure 2).
When the contribution of unstructuredness among these proteins
was investigated, interestingly, it was found that except for
carbohydrate metabolism and electron transport, proteins in-
volved in all other important processes in the HD were
significantly enriched in unstructured proteins (Figure 3A).
Likewise proteins in ‘‘PD dataset’’ were found to have
significantly enriched participation in neuronal activities, signal
transduction, cell proliferation and differentiation, immunity and
defense, apoptosis and its regulation, protein metabolism, cell cycle
(Figure 2) and the proteins involved in these processes were
largely unstructured (Figure 3B).
Analysis of the proteins in ‘‘AD dataset’’ revealed significantly
enriched participation in neuronal activities, signal transduction,
developmental processes, cell proliferation and differentiation,
coenzyme and prosthetic group metabolism, immunity and
defense, apoptosis and its regulation, oncogenesis, transport,
protein metabolism and modification, cell cycle and intracellular
protein traffic etc (Figure 2). Barring processes like coenzyme
and prosthetic group metabolism and immunity and defense,
proteins involved in all other important processes in the AD were
significantly unstructured (Figure 3C).
Discussion
Computational estimates suggest that eukaryotic proteomes
have a significantly higher occurrence of disordered proteins
relative to prokaryotic proteomes [4]. The prevalence of
intrinsically unstructured proteins in eukaryotes is likely to be
due to more complex signaling and regulatory pathways that
heavily rely on disordered proteins [24]. While much has been
studied about the general mechanisms of protein-protein interac-
tions, the specific structural features that account for differences in
protein interactivity has recently been ascribed to ‘‘fuzzy’’ complex
formation and are largely unknown [2]. In case of disordered
proteins this interaction network is much more complex and vast
compared to that of the ordered/globular proteins [24]. These
proteins do not have a fixed structure and hence they are flexible
with a tendency to interact with many other proteins.
It has been established by other groups that partially or fully
disorderd proteins are prevalent in complex disorders like
neurodegenerative diseases [25], cancer, cardiovascular disease
or diabetes [8] and led to the ‘‘disorder in disorder (D2)’’ concept
[26]. Here we have investigated the content of unstructuredness in
HD, PD and AD datasets, the commonest of neurodegenerative
diseases, which shows significantly high prevalence of unstructured
proteins in most of these diseases and the extent of unstructured-
ness is comparable to the previous reports. Proteins in Hunting-
ton’s disease (HD dataset) were found to be most unstructured.
HD being a monogenic disorder, this is somewhat expected as all
the pathologically important proteins should interact with the
Table 1. Prevalence of Unstructured proteins in HD, PD and AD.
Type Size of dataset Percentage unstructuredness Z values* [C1] Z values* [C2]
HD 147 81.6 1.80 6.8
PD 65 75.4 NS
# 3.3
AD 140 80.7 1.94 5.3
Control dataset 1 [C1] 17159 73.4 – –
Control dataset 2 [C2] 264 47.7 6.39 –
Control dataset 3 [C3] 117 76.9 NS
# 4.6
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implicated, multiple hubs should be there and we considered only
one such hub. It has earlier been reported that a correlation exists
between unstructuredness and the complexity of an organism
[4,27]. It is speculated that for a particular protein, the more it is
unstructured, the more is its possibility to interact with diverse
partners, and hence the interaction network of the protein
becomes large and complex [28]. Analysis of unstructuredness
among HD, PD and AD dataset reveals that the hub proteins in
these datasets (those interacting with 10, 5 or 20 partners) are
more unstructured than the end proteins (Figures 1C, 1D and
1E). It has been previously reported that hubs should have more
unstructured residues [22]. Our findings from a different perspective
conform to that. It also subscribes to the evolutionary model of
network organization by hub proteins [23], possibly through ‘‘fuzzy’’
complex formation [2]. It can be suggested that in a disease protein
network, loss of interactions around the hub over time could
ankylose the network leading to its failure. However, this could just
be an indirect consequence of the prevalence of unstructured
proteinsinthe networkandhenceitwouldbepremature to guessthe
impacts of ‘‘hubs’’ on such networks.
Interestingly, the types of ‘‘biological processes’’, where the
components of the individual datasets are found to participate
significantly, are very much characteristic of the functional/
Figure 1. Intrinsically unstructured proteins are prevalent in neurodegenerative disease dataset. A: Considering all the 352 members of
the disease datasets, about 80% of the proteins were found to be unstructured compared to 73.4% and 47.7% in ‘‘control datasets 1 and 2’’
respectively. Level of significance was calculated by Z-test and the Z-values indicate that unstructuredness is highly prevalent in the disease dataset
compared to ‘‘control datasets 1 and 2’’ (denoted by * and #). B: The percentage of proteins in HD, PD and AD datasets with $40 to $100
consecutive residues unstructured compared to ‘‘control datasets 1 and 2’’. Levels of significance was calculated by Z-test throughout indicating
significant prevalence of proteins having $40 to $100 consecutive residues unstructured in the HD datasets compared to ‘‘control dataset 1’’ and
denoted by $ in each cases. In PD and AD dataset no such significant prevalence was observed. However, compared to ‘‘control dataset 2’’ proteins
having $40 to $100 consecutive residues unstructured are significantly enriched in HD, PD and AD datasets and denoted by #. C, D & E:
Unstructuredness is significantly prevalent in the ‘‘hub’’ proteins involved in neurodegenerative diseases. All the proteins in HD, PD
and AD datasets were analyzed for the presence of ‘‘hub’’ and ‘‘end’’ proteins and the percentage of IUPs among the ‘‘hub’’ and ‘‘end’’ proteins in the
disease datasets were calculated and plotted. Irrespective of the definition of ‘‘hub’’ (protein with $10 interactors (C), protein with $5 interactors (D)
or protein with $20 interactors (E), IUPs were significantly prevalent among ‘‘hub’’ proteins. Levels of significance were calculated by Student’s t-test
and P values were 0.014 (C), 0.011 (D) and 0.012 (E) respectively, indicated by * in each panel.
doi:10.1371/journal.pone.0005566.g001
IUPs in Neurodegeneration
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found that components participating in these biological processes
are also enriched with unstructuredness. Consequently, it could be
summarized that not only these neurodegenerative disease datasets
are enriched in unstructured proteins but also most of these
unstructured proteins play pivotal role in the disease pathogenesis
by participating in vital biological processes.
Conventional wisdom suggests that genes known to cause
disease should predominantly encode ‘‘hubs’’ [29–31]. Expanding
their analysis to include human orthologs of mouse genes involved
in pre- or post-natal lethality, Goh K.–I. et al. [32], however,
observed an ‘‘unexpected peripherality’’ of the disease causing
genes in the sense that essential genes were found to be clustered
into ‘‘hubs’’ and were not involved in diseases. In a later study
Feldman I. et al. [33] pointed out that the correlation between the
parameters ‘‘essentiality’’ and ‘‘connectivity’’ should not be
deterministic. Using a bigger size of data (Goh K. -I. et al. used
a limited number of data from OMIM) Feldman I et al. did notice
functional clustering of disease genes despite the limited knowledge
of the human interactome. In our study, excepting the single
disease causing genes for each disorder, we did not categorize
other components in terms of their ability to cause disease. Rather
we focused on constructing the network in terms of protein
structural disorder and the ‘‘essentiality’’ parameter has not been
considered. How exactly the clustering, that we observed, would
be correlated to ‘‘essentiality’’ is not a simple question to address
and would demand a separate analysis. But in the IUP scenario,
where the proteins are multitasking and the functions are context
based, it would be interesting to apply Goh et al.’s approach and to
see how the boundary between the ‘‘disease’’ and ‘‘essential’’ genes
are drawn.
Interestingly, even if the disorder in the overall ‘‘disease dataset’’
was significantly high (Figure 1A) in comparison to ‘‘control
dataset 1’’, the ‘‘PD dataset’’ failed to show this behavior. This is
probably due to insufficient experimental data available for PD or
the interactome of a-synuclein could be highly underrepresented
in the databases. In recent times a lot of efforts are being given in
understanding the biology of PD [34 and references therein] and it
is realized that the disease may be an outcome of the dynamic
interplay between a-synuclein and its close homologue b-
synuclein, both unstructured proteins. The discrepancy that we
noticed in the PD dataset may also be a result of a different
interaction pattern in this disease. Similar trend was observed in
breast cancer proteins when ‘‘control dataset 3’’ was compared to
‘‘control dataset 1’’ although it is reported that unstructuredness is
prevalent in cancer [6]. It is to be noted further that we considered
the human proteome alone as control for our analysis, whereas a
selection of the whole eukaryotic proteome would have less
disorder, as it was the case (,35–51%) in the analysis by Dunker
A.K. et al. [4] using PONDR tools, since the disorder contribution
from lower eukaryotes was much less there. To justify, we used a
‘‘biased’’ ‘‘control dataset 2’’ (comprising of metabolic enzymes
which have known PDB structure) throughout where the
distribution was different, as expected. What we observed in the
Figure 2. Functional annotations of the proteins in disease datasets. All the protein IDs for HD, PD and AD datasets were submitted
separately in batch to annotate the biological process by the ‘‘PANTHER biological process’’ annotation tool and the results were tabulated and
analyzed. Biological processes that were significantly enriched with proteins in HD, PD and AD protein datasets compared to total human proteome
dataset are indicated in figure by # (for HD), * (for PD) and $ (for AD). Level of significance in each case was calculated by Chi-square test. Chi-square
test was performed and p values were calculated with the aid of ‘‘GraphPad QuickCalcs’’ (http://www.graphpad.com/quickcalcs/chisquared1.cfm).
doi:10.1371/journal.pone.0005566.g002
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PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5566Figure 3. Prevalence of unstructuredness in biological processes enriched with proteins from HD, PD and AD datasets. A: Except for
carbohydrate metabolism and electron transport, proteins involved in all other important biological processes, as indicated, are significantly enriched
in unstructured proteins in HD. Levels of significance were calculated by Z-test indicating confidence level of 95% in each case. B: Proteins involved in
all the important processes in PD as shown in figure are significantly enriched in unstructured proteins. Levels of significance were calculated by Z-
test indicating confidence level of 95% in each case. C: Except processes like coenzyme and prosthetic group metabolism and immunity and defense,
proteins involved in all other important processes in AD, as mentioned, are significantly enriched in unstructured proteins.
doi:10.1371/journal.pone.0005566.g003
IUPs in Neurodegeneration
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disorder. In other words, it not only confirms the robustness of
the tool we used but also our data suggests that in higher
organisms disorder is more prevalent leading to increasing
interaction complexity.
Additionally, longer stretches of unstructured regions are more
prevalent in proteins of ‘‘HD dataset’’. It is not clear whether it has
anything to do with HD pathogenesis. However, increasing length
of polyQ stretch in Htt is directly correlated with the age at onset
of the disease [35] and intrinsic unstructuredness in the polyQ
region [15]. It is also reported that in lower organisms the polyQ
length is smaller [36]. A tripartite model correlating the length of
protein unstructuredness, its influence on disease outcome and the
network complexity, is still elusive.
In conclusion, the fact that ‘‘unstructured’’ proteins are
prevalent in ‘‘complex’’ disorders and not necessarily in any kind
of genetic disorder, and the observation that they cluster around
network ‘‘hubs’’, may have far reaching consequences in the
pursuit of a ‘‘specific’’ solution to these diseases.
Methods
Construction of datasets
For analysis, databases were constructed using the following
criteria: (A) Proteins involved in HD, PD and AD were retrieved
directly from the NCBI’s (Http://ww.ncbi.nlm.nih.gov) Entrez
Gene database using keywords ‘‘Huntington disease Homo
sapiens’’, ‘‘Parkinson disease Homo sapiens’’ and ‘‘Alzheimer
disease Homo sapiens’’, respectively, for the three diseases. (B)
Extensive literature survey was done for reports of proteins
interacting with the hubs of the diseases (Huntingtin (Htt) in HD,
Amyloid precursor protein (APP) in AD and a-synuclein in PD),
primarily determined through high to moderate throughput
protein-protein interaction (PPI) or expression studies (e.g., co-
immunoprecipitation [37] or microarray analysis [38]) (C) Both
the datasets, (A) and (B), were now combined. In case of AD or PD
the number of novel hits from step (B) were less, whereas about
115 interactors were incorporated from literature in case of HD
(see Table S1 and S2 for references). These enriched datasets were
now checked for non-redundancy, any repetition was eliminated,
and they were further filtered to remove genetic association results.
We realized that the datasets obtained through keyword ‘‘text’’
search carry a finite probability of false positives as well as
inadvertent ‘‘misses’’. In addition, those retrieved through ‘‘high-
throughput’’ (genomics or proteomics) studies reportedly contain
large number of false positives [39]. Thus, understandably to some
extent, the datasets would be ‘‘noisy’’ and biased towards network
‘‘hubs’’ chosen. To avoid this problem, we adopted a stringent
filtering criteria where each protein of these datasets were checked
to ascertain that their interaction was either physically validated by
some other experiment or they had a direct functional implication
in the disease pathogenesis as reported in the literature. Some of
these studies reported physical interactions of Htt, APP or a-
synuclein with mouse proteins. In the dataset we incorporated the
human homologues of these proteins, if available. The refined
subsets of proteins now had a direct relevance to the diseases and
were designated as ‘‘HD dataset’’ (Table S1 and S2), ‘‘PD dataset’’
(Table S3 and S4) and ‘‘AD dataset’’ (Table S5 and S6)
respectively. Individual protein sequences were extracted from
SWISSPROT database (release 55.0) (http://www.SwissProt.org)
using protein IDs.
Along with these datasets, three control datasets were
constructed. This first one, ‘‘control dataset 1’’ consisted of
17159 human proteins obtained using SwissProt sequence retrieval
system (SRS) by searching the query ‘‘[swiss_prot-Organism:
homo sapiens*] ! [swiss_prot-Keywords: disease*]’’. This control
dataset was constructed to check the trend for all human proteins
from the SwissProt database that are not annotated to be involved
in any disease.
A second control (‘‘control dataset 2’’) (Table S7) was
constructed which was biased in favor of the conventional wisdom
of the ‘‘structure-function’’ paradigm. Initially the dataset
consisted of all the enzymes (presumed to have more ordered
structure) taken from databases like ‘‘Brenda’’ (Http://www.
brenda.uni-koeln.de/) and KEGG, (Http://www.genome.jp/
kegg/), involved in various metabolic and biosynthesis pathways
like Glycolysis/Gluconeogenesis, TCA cycle, PPP pathway, Starch
metabolism, Urea cycle, Fatty acid synthesis, Fatty acid metab-
olism, Purine metabolism, Pyrimidine metabolism, Bile acid
synthesis. Galactose metabolism, Sterol biosynthesis, Nucleotide
sugar metabolism, Lysine biosynthesis, Gly-Ser, Thr metabolism,
Fructose mannose metabolism, amino sugar metabolism, sphin-
golipid metabolism, degradation and synthesis of ketone bodies,
glutamate metabolism, tyrosine metabolism, histidine metabolism,
inositol metabolism, Glycerophospholipid metabolism, Cysteine
metabolism, Valine, Leucine, Isoleucine biosynthesis, Phenylala-
nine metabolism, Alanine metabolism, Valine leucine isoleucine
degradation, Arginine proline metabolism, Beta alanine metabo-
lism, Riboflavin metabolism, Lipopolysaccharide biosynthesis,
Folate Biosynthesis, Porphyrin metabolism and N-glycan biosyn-
thesis. This raw dataset (consisting of 380 enzymes) was filtered to
contain only those enzymes which have known structures
submitted to PDB (http://www.rcsb.org). This ‘‘control dataset
2’’ (see Table S7), consisting of 264 metabolic enzymes with
known structures, was non-homologous to our disease datasets as
these were not the types of proteins usually involved in
neurodegenerative processes. We included this control in our
analysis to compensate for false positives/negatives.
The third control dataset, ‘‘control dataset 3’’, consisted of 117
human proteins obtained using SwissProt sequence retrieval
system (SRS) by searching the query ‘‘[libs={swiss_prot
trembl}-Organism: homo sapiens*] & [libs-Description: breast*
& cancer*] ’’ (see Table S8). This control dataset was constructed
to check the trend for the proteins involved in a non-
neurodegenerative disease to validate if the involvement of IUP
was specific for neurodegeneration or more generally related to
diseases.
Disorder Prediction
Several disorder prediction tools are available to find out
disorder regions in proteins [40–48]. Several studies [44–49]
compared the efficacies of these tools and the general conclusion
was that performances of FoldIndex and PONDR VL-XT were
comparable. FoldIndex uses charge-hydropathy classification
originally proposed by Uversky and gives a single index (R) for
the entire protein, with a reported accuracy rate of 77% [44]. On
the other hand, PONDR-VLXT gives a per residue output based
on a neural network prediction with a reported accuracy rate of
72% [44]. We did a random statistical analysis of a few easily
available tools [40–48] and found out that FoldIndex is definitely
one of the better ones (see Text S1). Even though an updated
version of PONDR is now available, due to the ease of use in
batch through a customized Perl script, we used FoldIndex to
classify proteins in terms of unstructuredness. Considering the fact
that a large number of false positives/negatives would occur in our
constructed datasets, due to conspicuous incompleteness of
experimental information, we realized that as predictions were
done on the basis of sequence features, use of a single binary
IUPs in Neurodegeneration
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noted that in the dynamic models of ‘‘fuzzy’’ complexes [2], just a
stretch of intrinsic disordered region (IDR) could be sufficient for a
protein to behave as an IUP. Hence, occurrence of a stretch of 30
continuous residues in a protein, whether or not FoldIndex
classified the protein as an IUP as a whole, was also considered as
a metric for IUP in our model. Therefore, we considered a protein
to be ‘‘unstructured’’ if (A) it was indexed by FoldIndex (R,0) as
an IUP and/or (B) it contained a stretch of 30 consecutive
unstructured residues. The unstructured datasets were constructed
based on these criteria as described in Table 1.
Interaction and function
The basis of our analysis was the disease datasets, comprising of
unique interactors of disease-gene products, which were manually
verified as described before. We searched the interaction database
BIOGRID v. 2.0.36 [50] to find out the possible number of
interactors, reported till date, of the proteins that are present in the
disease datasets. HD being a monogenic disease, huntingtin (htt)
gene was considered to be the ‘‘hub’’ in the network. For AD and
PD, mutations in multiple genes (APP, PS1, PS2) are implicated,
while specific allele of APOE4 consistently increase the risk of
familial AD (,5% of total AD incidence). In PD, disease causing
mutations at a-synuclein, b-synuclein, PARK2, PARK5 and
PARK7 have been identified. However, the genetic reasons
behind a large number of familial PD cases are still unknown.
Therefore, for these two diseases, the network architecture would
have multiple ‘‘hubs’’ with overlaps. To avoid confusions, the two
main unambiguously known causative genes i.e., APP and a-
synuclein for AD and PD respectively, were considered to
construct the respective datasets. Considering that many novel
Htt interacting proteins present in the HD dataset obtained from
the literature were hardly studied and hence very little or no
information was available about their interactions and functions in
BIOGRID. Similar were the findings for several AD and PD
dataset proteins. On the other hand, for several functionally
significant proteins extensive information was already available.
There is a definite possibility of biasness during the measurement
of the correlation between disorderedness and the number of
interactors of the proteins. However, following Haynes et al., we
chose ten partners as a cutoff value for a protein designated to be a
‘‘hub protein’’ [24]. But deviating from Haynes et al., we
designated all the proteins with less than 10 interactors as ‘‘end
proteins’’. To eliminate any possible biasness in the definition of
‘‘hub’’ and ‘‘end’’ proteins, we varied the cutoff values for ‘‘hub’’
proteins in two consecutive validation analyses and rather than
defining a protein with more than 10 interactors as a ‘‘hub’’, those
with more than 5 or 20 interactors in the disease datasets were
defined as ‘‘hubs’’ respectively. In each case ‘‘end proteins’’ were
defined as those having less than 5 or 20 interactors respectively.
We calculated the percentage of IUPs among the ‘‘hub’’
proteins in the three disease datasets separately, grouped them,
calculated the mean and the standard deviation, and defined the
value as percentage of IUPs in neurodegenerative disease datasets.
To test significant abundance of IUPs among hub proteins
Student’s t-test was performed and p values were calculated with
the aid of ‘‘GraphPad QuickCalcs’’ (Http://www.graphpad. com/
quickcalcs/ttest1.cfm?Format=SD). The percentage unstructu-
redness in End proteins was calculated in a similar way.
Functional Classification of Unstructured Proteins in
Neurodegenerative Diseases
To decipher the range of functions where the IUPs
participate, functional annotations were done using PANTHER
server (Http://www.pantherdb.org/). PANTHER is a compre-
hensive database designed to relate protein sequences to
functions [51]. Functions were searched for all the proteins in
the disease (HD, PD and AD) datasets. All the protein IDs for
the three disease-datasets were submitted separately in batch to
annotate the biological process in the ‘‘PANTHER’’ annotation
tool and the results were tabulated and analyzed. To find
significant contribution of any ‘‘biological processes’’ in the
disease datasets, the annotations were compared with that for
the total human proteome and chi-square tests were performed
to calculate the p values. Also to find out significant
contribution of unstructuredness in any biological processes,
we needed to compare the entire ‘‘unstructured’’ protein
population with respect to the ‘‘structured’’ population under
each process category and Z-tests were carried out according to
S p i e g e le ta l[ 5 2 ] .
Supporting Information
Text S1 Statistical Analysis Prior to Disorder Prediction
Found at: doi:10.1371/journal.pone.0005566.s001 (0.01 MB
PDF)
Table S1 Huntington’s disease Protein Dataset. Proteins that
contain %30 amino acids residues unstructured at a stretch are
tabulated here
Found at: doi:10.1371/journal.pone.0005566.s002 (0.01 MB
PDF)
Table S2 Huntington’s disease Protein Dataset. Proteins that
contain &30 amino acids residues unstructured at a stretch are
tabulated here
Found at: doi:10.1371/journal.pone.0005566.s003 (0.02 MB
PDF)
Table S3 Parkinson’s disease Protein Dataset. Proteins that
contain %30 amino acids residues unstructured at a stretch are
tabulated here
Found at: doi:10.1371/journal.pone.0005566.s004 (0.01 MB
PDF)
Table S4 Parkinson’s disease Protein Dataset. Proteins that
contain &30 amino acids residues unstructured at a stretch are
tabulated here
Found at: doi:10.1371/journal.pone.0005566.s005 (0.01 MB
PDF)
Table S5 Alzheimer’s disease Protein Dataset. Proteins that
contain %30 amino acids residues unstructured at a stretch are
tabulated here
Found at: doi:10.1371/journal.pone.0005566.s006 (0.01 MB
PDF)
Table S6 Alzheimer’s disease Protein Dataset. Proteins that
contain &30 amino acids residues unstructured at a stretch are
tabulated here
Found at: doi:10.1371/journal.pone.0005566.s007 (0.02 MB
PDF)
Table S7 Control dataset 2 consisting of metabolic enzymes
with known structures
Found at: doi:10.1371/journal.pone.0005566.s008 (0.01 MB
PDF)
Table S8 Control dataset 3 consisting of proteins involved in
Breast Cancer
Found at: doi:10.1371/journal.pone.0005566.s009 (0.08 MB
PDF)
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